Survival in Patients with Colorectal Cancer and Isolated Brain Metastases: Temporal Trends and Prognostic Factors from the National Cancer Database (2010–2020)
Open Access
Abstract
Background: The development of brain metastases (BM) is a relatively uncommon but significantly adverse event in the spread of colorectal cancer (CRC). Although management of CRC BM has improved with advances in imaging and systemic therapies, clinical outcomes remain poor. Methods: This retrospective cohort study used the U.S. National Cancer Database to evaluate survival outcomes, treatment patterns, and prognostic factors in CRC patients diagnosed with BM between 2010 and 2020. Patients with isolated brain-only metastases formed the primary analytic cohort, while those with additional extracranial metastases were included for descriptive comparison. Multivariable Cox proportional hazards and logistic regression models were used to assess factors associated with of survival. Proportional hazards assumptions were tested using Schoenfeld residuals. Accelerated failure time models were also employed. Results: From a cohort of 1,040,877 individuals with CRC, 795 had metastatic disease present along with relevant data, of which 296 had isolated BM. Median overall survival (mOS) in BM-only metastatic disease group was 7.82 months (95% CI: 5.82–9.66). The longest survival was observed among patients treated with stereotactic radiosurgery combined with systemic therapy (SRS+Sys), with a median OS of 23.26 months (95% CI: 17.51–41.95) and a 3-year survival rate of 35.8%. In adjusted Cox models, SRS, systemic therapy, and definitive surgery of the primary site were each independently associated with reduced hazard of death. Rectal cancer patients had longer survival than those with colon primaries (mOS: 10.35 vs. 6.08 months). Age, comorbidity burden, and insurance status were not associated with survival in adjusted analyses. Conclusions: SRS+Sys was associated with longer survival compared to other treatment strategies. However, treatment selection is highly dependent on individual clinical factors such as performance status, comorbidities, and disease extent; therefore, these findings must be interpreted with caution Future prospective studies incorporating molecular and biomarker data are warranted to better guide care in this rare and high-risk group.Keywords
This publication has 36 references indexed in Scilit:
- Clinical features and prognostic factors of brain metastases from colorectal cancer: a single center experienceInternational Journal of Colorectal Disease, 2023
- Prognostic impact of tumor size on patients with metastatic colorectal cancer: a large SEER-based retrospective cohort studyUpdates in Surgery, 2023
- Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancerClinical and Translational Oncology, 2022
- Where Are We Now and Where Might We Be Headed in Understanding and Managing Brain Metastases in Colorectal Cancer Patients?Current Treatment Options in Oncology, 2022
- Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer—Who Are These Patients?Clinical Colorectal Cancer, 2021
- Access to Care, Cost of Care, and Satisfaction With Care Among Adults With Private and Public Health Insurance in the USJAMA Network Open, 2021
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Stereotactic Radiosurgery: Treatment of Brain Metastasis Without Interruption of Systemic TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Stereotactic radiosurgery in the treatment of brain metastases: The current evidenceCancer Treatment Reviews, 2014
- Poor Outcomes after Whole Brain Radiotherapy in Patients with Brain Metastases: Results from an International Multicentre Cohort StudyClinical Oncology, 2013